PHM de Mulder - Concepedia

Author

PHM de Mulder

Also Known As

D Paes, P DE MULDER, P De Mulder, P de Mulder, P. De Mulder, P. Mulder, P. de Mulder, PHM De Mulder, PHM de Mulder, on behalf of the EORTC Genitourinary Group

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Rotterdam University of Applied Sciences Erasmus MC Cancer Institute Radboud University Medical Center Antwerp University Hospital

About

PHM de Mulder is an author at Radboud University Nijmegen specializing in oncology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.3K
2	Immunology	3	3	63
3	Pathology	3	3	111
4	Pharmacology	2	2	47
5	Health Sciences	1	1	86

PHM de Mulder

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel, European Journal of Cancer Year UpdateUrologySurgical OncologyGenitourinary CancerMedicine	2005	542
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients Ivar Bleumer, Alexander Knuth, Egbert Oosterwijk, British Journal of Cancer	2004	173
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Peter Palmer, J. Vinke, Thierry Philip, Annals of Oncology Prognostic FactorsUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	1992	156
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck G. Catimel, Jan B. Vermorken, M. Clavel, Annals of Oncology MedicineLy 188011Phase Ii StudyHead And Neck CancerDermatology	1994	135
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group R. de Wit, G. Stoter, Dirk Th. Sleijfer, British Journal of Cancer UrologySurgical OncologyGenitourinary CancerMedicineCancer Management	1995	99
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study D. Schrijvers, C. van Herpen, Joseph Kerger, Annals of Oncology Neck CancerMedicineUnresectable HeadHead And Neck CancerCancer Treatment	2004	86
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) Carla M.L. van Herpen, Laura D. Locati, Jan Buter, European Journal of Cancer Eortc 24982Malignant DiseaseMedicinePathologyPhase Ii Study	2008	64
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Ronald de Wit, Laurence Collette, Richard Sylvester, British Journal of Cancer UrologyEndocrine-related CancerGenitourinary CancerMedicineSerum Alpha-fetoprotein Surge	1998	42
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer R. de Wit, Richard Sylvester, C Tsitsa, British Journal of Cancer Marker Half-lifeUrologyMarker ConcentrationGenitourinary CancerMedicine	1997	30
Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam David Cunningham, M. Dicato, Jaap Verweij, Annals of Oncology OncologyRepeat CoursesPharmacologyMetronomic TherapyOptimum Anti-emetic Therapy	1996	30

Page 1